Horizontal Ridge Augmentation in Mandible Usign ROG + ESWT
NCT ID: NCT03785717
Last Updated: 2018-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2016-08-31
2018-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Assessing the efficacy of horizontal augmentation and percentage of reabsorption of bone graft material in the technique of guided bone regeneration (GBR), combined with the shock wave therapy (SWT) in the horizontal bone reconstruction of mandibular alveolar ridges.
Type of study:
Triple blind randomized clinical trial
Population and sample:
Twenty six patients of university and private clinical practice, who require augmentation of horizontal ridge in the mandible for back placing of an implant, and their compliance with inclusion and exclusion criteria, will be assessed.
Type of analysis:
Central trend and dispersion (medium and standard deviation) measurements will be obtained. Type of data distribution using Shapiro Wilk.
t-student test between no related groups for assessing bone augmentation. t-paired test between related groups for assessing pre and post treatment within the same group.
t test for proportion difference, in order to assess the percentage of reabsorption of bone graft, bone density, bone quality, within a same group.
Fisher, group comparison.
A multiple linear regression model will be developed in order to establish if the difference among groups is influenced by the initial width of the ridge and the thickness of the soft tissue.
In case of not following a normal distribution, no parametrical tests for related and no related groups and logistic regression, will be used.
The frequencies of adverse effects in each group will be obtained, and compared to the Chi2 test or the Fisher exact test.
All the analyses will be made with significance level of 5% (p\< 0.05).
Effect measurements: Relative Risk (RR), Attributable Risk Reduction (ARR), and Necessary Number to be Treated (NNT). The augmentation of horizontal volume that allows the installation of a ≥4.1 mm implant will be taken as cutting point reference of clinical success.
Expected Results:
* Establishing the effect of the shock wave therapy, in combination with guided bone regeneration, on the improvement of bone augmentation and the decrease of bone graft reabsorption.
* Establishing the effect of shock wave therapy, in combination with guided bone regeneration, on the improvement of bone quality and density, as well as on decreasing the adverse effects.
* Acquiring new knowledge in the area of bone reconstruction.
* Presentation of results in local and international congresses.
* Formation of human resource; mastery graduation paper on Dentistry Science Master.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ROG only
cancellous (1-2 mm) \& cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
ROG
Bone width augmentation using bone grafting and membrane non cross linking.
ROG & ESWT
Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
ROG & ESWT
cancellous 1-2mm \& cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
ROG
Bone width augmentation using bone grafting and membrane non cross linking.
ROG & ESWT
Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ROG
Bone width augmentation using bone grafting and membrane non cross linking.
ROG & ESWT
Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Partial mandibular edentulism requiring at least two teeth to be replaced with osseointegrated implants
* Patient with alveolar ridge thickness of ≤4mm, evaluated by CBCT
* Vertical bone availability of 9mm to anatomical structure such as a chin or dental canal that allows a short implant placement of 8mm at the end of the study.
* Extractions performed ≥ 6 months
* Elderly patients between 35 and 65 years old
* Patients without current disease or with chronic pathologies in medical control that does not affect the healing processes such as: controlled hypertension, controlled hypothyroidism, controlled hypercholesterolemia
* Evaluated by anamnesis and laboratory tests that rule out processes of immunosuppression, glycemia and coagulation disorders hypercholesterolemia
* No smoking
Exclusion Criteria
* Immunosuppressive drugs
* Anti-coagulated or with dual anti-platelet aggregation
* Therapy with bisphosphonates
* Hormone replacement therapy
* Patient with a history of radiotherapy of the head and neck
* Pregnant women or nursing
* Permanent consumption of NSAIDs and corticosteroids
* Prolonged antibiotic therapy in the last 6 months
35 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gloria Lafaurie
UNKNOWN
Carlos Leal
UNKNOWN
Universidad El Bosque, Bogotá
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yamil Lesmes
DDS, MSc candidate
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yamil Lesmes
Role: PRINCIPAL_INVESTIGATOR
Universidad El Bosque
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yamil Lesmes
Bogotá, , Colombia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCI2015-8351
Identifier Type: -
Identifier Source: org_study_id